Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Michael McVey Lusk who wrote (598)	1/14/1998 12:33:00 AM
From: Keith Hankin	Read Replies (2) \| Respond to of 1728

The posting about the deal with Genetics Institute brings up an interesting question that I think could bring up some good discussions: How well do people think that the companies that have the content (databases) will do in the market versus the companies that have the technology (AFFX, INCY, etc)? Which are better short-term and long-term investments?

To: Michael McVey Lusk who wrote (598)	1/14/1998 3:24:00 PM
From: Michael McVey Lusk	Respond to of 1728

I'm glad to see another of these EasyAccess agreements - another heavy hitter placing some serious dough on Genechip. One thing bothers me a bit, though: there is no mention of possible royalties on therapies developed by the DiscoverEase participants. "Under the terms of the three-year Affymetrix agreement, GI will pay Affymetrix more than $4 million annually in technology access fees along with payments for custom chip designs and chips. Affymetrix may also receive payments based on use of GeneChip technology and access to related database information by DiscoverEase program participants. No further terms of the agreement were disclosed."